iTeos Therapeutics (NASDAQ:ITOS) Lowered to Neutral Rating by HC Wainwright
HC Wainwright cut shares of iTeos Therapeutics (NASDAQ:ITOS – Free Report) from a buy rating to a neutral rating in a research note issued to investors on Wednesday, MarketBeat.com reports. HC Wainwright also issued estimates for iTeos Therapeutics’ Q2 2025 earnings at ($0.82) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.44) […]
HC Wainwright cut shares of iTeos Therapeutics (NASDAQ:ITOS – Free Report) from a buy rating to a neutral rating in a research note issued to investors on Wednesday, MarketBeat.com reports. HC Wainwright also issued estimates for iTeos Therapeutics’ Q2 2025 earnings at ($0.82) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.44) […]
